Cancer cells harboring activating mutations in PIK3CA exhibit increased sensitivity to PI3K inhibition (Miller et al., 2010; Sanchez et al., 2011; Maira et al., 2012), suggesting that this class of drugs may be most effective against tumors with mutations in the PI3K pathway. The gene discussed is PIK3CA; the disease is cancer.